Investigations of [89Zr]atezolizumab in patients with NSCLC, TNBC, and bladder cancers have captured the PD-L1 levels in all the lesions in entirety and the inter and intra-tumoral heterogeneity in PD-L1 expression. The gene discussed is CD274; the disease is urinary bladder carcinoma.